Clinical Trials Browser

Phase 4 × Has results × Erlotinib Hydrochloride × Clear all

NCT00949910 2016-10-05

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 4 Completed

6,586 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01609543 2016-02-01

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Phase 4 Completed

62 enrolled 8 charts

Non-Squamous Non-Small Cell Lung Cancer

NCT02000531 2016-01-13

Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

Phase 4 Completed

45 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01196078 2015-07-27

A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Phase 4 Completed

114 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01287754 2015-06-02

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Phase 4 Completed

24 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01230710 2015-03-30

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

Phase 4 Completed

51 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung